# Arrowsmith

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arrowsmith

- Industry: Pharmaceuticals
- Headquarters: Tsukuba, Japan
- Website: https://arrowsmith.co.jp
- Total disclosed funding: $6.5M
- Latest round: Series A (Jun 22, 2026)
- Investors on record: 4

## About

Based in Japan, Arrowsmith Inc. d.b.a Arrowsmith focuses on developing innovative software solutions that enhance operational efficiency and data management for various industries, including logistics, manufacturing, and retail. Arrowsmith Inc. was founded in 2025 in Tsukuba, Japan. The company specializes in advanced software solutions tailored to meet the operational needs of businesses. In June 2026, Arrowsmith raised JPY 1.05 billion in series A funding from ANRI, DBJ Capital, JIC Venture Growth Investments and JAFCO Group. Arrowsmith Inc. specializes in innovative software solutions aimed at improving operational efficiency and data management across diverse industries. Their core offerings include advanced software designed to streamline processes and enhance data accuracy, serving clients from large enterprises to small and medium-sized businesses primarily in Asia and North America. The solutions focus on user-friendly interfaces and robust functionality to aid end users in optimizing workflows and decision-making.Arrowsmith Inc. operates on a revenue model combining subscription services with direct sales to clients. The company offers tailored software packages that align with specific operational needs, allowing clients to subscribe to ongoing services that include support and updates. They cater to various scales of operations, ensuring flexibility for individual businesses and larger corporate clients, with key products forming the backbone of steady cash flow through recurring subscriptions and long-term partnerships. In June 2026, Arrowsmith raised JPY 1.05 billion in series A funding from ANRI, DBJ Capital, JIC Venture Growth Investments and JAFCO Group. The company plans to use June 2026 funds to advance clinical trials of ARW001 and support research and development of its subsequent pipeline candidates.

## Funding rounds

- Series A, Jun 22, 2026, $6.5M — JAFCO Group, ANRI, DBJ Capital, JIC Venture Growth Investments

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- ANRI (https://capitalatlas.ai/funds/anri) — Series A
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series A
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series A